Lyfegen raises CHF 5M to scale drug rebate platform globally

Lyfegen, a Swiss provider of drug rebate management technology, has closed an additional CHF 5M in Series A funding. The investment will expand the company into new markets and enhance its platform’s global adoption.

Venture Leaders alumnus Lyfegen, a provider of drug rebate management technology, has secured an additional CHF 5 million in its Series A funding round. Led by TX Ventures, with participation from aMoon and other institutional investors, the funds will support Lyfegen's global expansion and innovation, targeting markets beyond Europe.

Rising drug costs and the complexities of managing rebate agreements pose challenges for the healthcare industry. Lyfegen addresses these issues with an automated platform that streamlines compliance, improves efficiency, and enables real-time tracking.

Currently, over 50 healthcare organizations in 8 markets use Lyfegen’s platform to manage more than 4,000 rebate agreements, track USD 1 billion in pharmaceutical revenue, and oversee $0.5 billion in rebates annually. Deployed across Europe, North America, and the Middle East, the platform simplifies rebate processes, reduces errors, and supports better financial performance.


Michel Mohler, CFO and Co-Founder of Lyfegen (Venture Leaders Technology 2023)